
Long noncoding RNA ROR regulates chemoresistance in docetaxelresistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway


Supplementary Materials

Supplemental Table 1: Initial profiling of lncRNAs in docetaxel-resistant cells (SPC-A1/DTX and H1299/DTX) compared with parental cells (SPC-A1 and H1299)


	LncRNAs	fold-change	
1	CUST_421_PI428631609	9.972491	
2	pl053552	9.575738	
3	lnc-ROR	9.053626	
4	CUST_2222_PI428631609	8.7036495	
5	CUST_6987_PI428631609	8.667568	
6	pl011310	8.39463	




Supplementary Figure 1: (A) Colony formation assays to measure cell proliferation in parental cells (SPC-A1 and H1299) transfected with linc-ROR or miR-145 inhibitor or FSCN1, and docetaxel-resistant cells (SPC-A1/DTX and H1299/DTX) transfected with sh-ROR or miR-145 mimics or sh-FSCN1. (B, C) Flow cytometry analysis to measure apoptosis and cell cycle in H1299 cells transfected with linc-ROR or miR-145 inhibitor or FSCN1, and H1299/DTX cells transfected with sh-ROR or miR-145 mimics or sh-FSCN1. (D) Differences lncRNAs expression levels between mixture A (SPC-A1 and H1299) and mixture B (SPC-A1/DTX and H1299/DTX). The expression level of linc-ROR was significantly upregulated in mixture B (9.05-fold). (E) Expression level of linc-ROR in parental and docetaxel-resistant LAD cell lines. Data are presented as mean \pm standard error based on at least three independent experiments. *p < 0.05, **p < 0.01.



Supplementary Figure 2: (A) Western blotting analysis of the expression of epithelial markers (E-cadherin, β-catenin) and mesenchymal markers (N-cadherin, vimentin) in parental cells transfected with linc-ROR or miR-145 inhibitor or FSCN1, and docetaxel-resistant cells transfected with sh-ROR or miR-145 mimics or sh-FSCN1. (B) Immunofluorescence analysis of the change in epithelial and mesenchymal markers in H1299 cells transfected with linc-ROR or miR-145 inhibitor or FSCN1, and H1299/DTX cells transfected with sh-ROR or miR-145 mimics or sh-FSCN1.





Supplementary Figure 3: (A) Transwell assays to determine cell migration and invasion ability of H1299 cells transfected with linc-ROR or miR-145 inhibitor or FSCN1, and H1299/DTX cells transfected with sh-ROR or miR-145 mimics or sh-FSCN1. (B) Wound healing assays to determine cell migration and invasion ability of parental cells transfected with linc-ROR or miR-145 inhibitor or FSCN1, and docetaxel-resistant cells transfected with sh-ROR or miR-145 mimics or sh-FSCN1. (C) Metastasis capacity of parental cells stably transfected with linc-ROR and docetaxel-resistant cells stably transfected with sh-ROR was partially reversed by miR-145 mimics and miR-145 inhibitor, respectively.